SRS Capital Advisors Inc. Raises Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

SRS Capital Advisors Inc. grew its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 419.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,851 shares of the pharmaceutical company's stock after buying an additional 1,495 shares during the quarter. SRS Capital Advisors Inc.'s holdings in Vertex Pharmaceuticals were worth $745,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently modified their holdings of VRTX. Dunhill Financial LLC increased its stake in shares of Vertex Pharmaceuticals by 70.6% in the 3rd quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company's stock worth $27,000 after purchasing an additional 24 shares in the last quarter. Legacy Investment Solutions LLC bought a new position in shares of Vertex Pharmaceuticals during the 3rd quarter valued at approximately $33,000. Brown Lisle Cummings Inc. purchased a new stake in Vertex Pharmaceuticals in the 4th quarter worth approximately $30,000. Truvestments Capital LLC bought a new stake in Vertex Pharmaceuticals during the 3rd quarter worth approximately $35,000. Finally, Capital Performance Advisors LLP purchased a new position in Vertex Pharmaceuticals during the third quarter valued at approximately $39,000. 90.96% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts recently issued reports on the company. StockNews.com cut Vertex Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Wednesday, February 19th. Oppenheimer cut shares of Vertex Pharmaceuticals from an "outperform" rating to a "market perform" rating in a research report on Thursday, December 19th. William Blair restated an "outperform" rating on shares of Vertex Pharmaceuticals in a research report on Friday, January 31st. JPMorgan Chase & Co. reduced their price target on shares of Vertex Pharmaceuticals from $503.00 to $500.00 and set an "overweight" rating on the stock in a report on Monday, December 23rd. Finally, Piper Sandler dropped their price objective on shares of Vertex Pharmaceuticals from $535.00 to $533.00 and set an "overweight" rating for the company in a report on Monday, January 27th. Eleven analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $506.70.

Insider Transactions at Vertex Pharmaceuticals

In related news, EVP Ourania Tatsis sold 244 shares of the firm's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $455.06, for a total transaction of $111,034.64. Following the sale, the executive vice president now owns 67,695 shares in the company, valued at approximately $30,805,286.70. This trade represents a 0.36 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold 1,084 shares of company stock valued at $505,512 in the last 90 days. 0.20% of the stock is currently owned by company insiders.

Vertex Pharmaceuticals Stock Up 1.1 %

Shares of VRTX stock traded up $5.42 during trading hours on Wednesday, reaching $491.64. 1,147,335 shares of the company's stock were exchanged, compared to its average volume of 1,495,791. The stock has a market cap of $126.25 billion, a PE ratio of -223.47, a PEG ratio of 2.11 and a beta of 0.41. The company has a current ratio of 2.69, a quick ratio of 2.35 and a debt-to-equity ratio of 0.01. The stock's fifty day moving average price is $443.51 and its two-hundred day moving average price is $461.12. Vertex Pharmaceuticals Incorporated has a 1 year low of $377.85 and a 1 year high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last announced its quarterly earnings data on Monday, February 10th. The pharmaceutical company reported $3.54 earnings per share for the quarter, missing analysts' consensus estimates of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative net margin of 4.86% and a negative return on equity of 2.02%. Research analysts predict that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current year.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.